Impact of the choice of an antiplatelet therapy for peripheral arterial disease: cost-effectiveness ratio and health economics assessment

P Priollet, G De Pouvourville - Journal des Maladies Vasculaires, 2007 - europepmc.org
therapy (clopidogrel and … no-choice of the most favorable strategy and the impact of these
losses of chances in terms of days of hospitalizations, to estimate the cost-effectiveness ratio of …

[HTML][HTML] Cost-effectiveness of coronary and peripheral artery disease antithrombotic treatments in Finland

E Soini, O Virtanen, S Väätäinen, JB Briere… - … in Therapy, 2020 - Springer
… Setting-Time-Effects-Perspective-Sensitivity analysis) reporting, … the deterministic incremental
cost-effectiveness ratio (ICER): … assessed the cost-effectiveness of antithrombotic treatment

Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands

JA Spoorendonk, JB Briere, K Bowrin… - … of medical economics, 2021 - Taylor & Francis
… is a cost-effective treatment option in stable CAD or PAD … 2 ) recommends antiplatelet
therapy as a pharmacotherapeutic … used to assess the number of events avoided, treatment and …

Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China

Z Lin, L Zhang, X Yang, L Liu, J Xuan - … of Medical Economics, 2020 - Taylor & Francis
Antiplatelet therapy is a … use of antiplatelets and the potential public health impact with
optimum clinical management of PAD in China, we conducted this cost-effectiveness analysis

[HTML][HTML] Screen or not to screen for peripheral arterial disease: guidance from a decision model

A Vaidya, MA Joore, AJ ten Cate-Hoek, H Ten Cate… - BMC Public Health, 2014 - Springer
… This study aims to determine the cost-effectiveness of one time … The results of cost-effectiveness
analysis were based on … the costs and health outcomes of only antiplatelet treatment are …

Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease

MR Cowie, A Lamy, P Levy, S Mealing… - Cardiovascular …, 2020 - academic.oup.com
… A Markov model was developed to assess the cost-effectiveness … costs resulted in an
incremental cost-effectiveness ratio (ICER) of £… Oral antiplatelet therapy in secondary prevention of …

Costeffectiveness of risk assessment and tailored treatment for peripheral arterial disease patients

A Vaidya, MA Joore, AJ ten Cate-Hoek… - Biomarkers in …, 2014 - Future Medicine
… we do not expect a significant impact of this simplification on the … – Costeffectiveness
analysis shows that the D-dimer-based risk … Antithrombotic therapy in peripheral artery disease: …

[HTML][HTML] Cost-effectiveness analysis of rivaroxaban plus aspirin compared with aspirin alone in patients with coronary and peripheral artery diseases in Italy

P Ferrara, PA Cortesi, D Di Laura, AP Maggioni… - Clinical Drug …, 2021 - Springer
… underlined antiplatelet therapy cost effectiveness in the … of this combination in the European
context has been assessed in … time that could affect cost effectiveness. Sensitivity analyses …

Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?

B Sigvant, M Henriksson, F Lundin… - European Journal of …, 2011 - academic.oup.com
… of this analysis was to evaluate the cost-effectiveness of … subjects should be offered anti-platelet
therapy for CV risk … when calculating incremental cost-effectiveness ratios (defined as …

Cost-effectiveness of medical, endovascular and surgical management of peripheral vascular disease

Z Fanari, WS Weintraub - Cardiovascular Revascularization Medicine, 2015 - Elsevier
… of cost-effectiveness analysis is to evaluate different health … , exercise programs, antiplatelets
therapy, strict diabetes … offer an impact on survival in addition to any expected impact of the …